A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong

International Journal of Clinical Practice

Volumn 61, Issue 3, 2007, Pages 403-410

  Chu, Leung Wing ^a   Yik, P Y ^a   Mok, W ^a   Chung, C P ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; GALANTAMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; CHINESE; CLINICAL TRIAL; COGNITION; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DETERIORATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHIATRY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; CHINA; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; FOLLOW-UP STUDIES; GALANTAMINE; HONG KONG; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847080422     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01284.x     Document Type: Article

References (25)

1. Cummings JL. Drug therapy: Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
2. Berg L, Morris JC. Diagnosis. In: Terry RD, Katzman R, Bick KL, eds. Alzheimer Disease. Philadelphia, Pennsylvania, USA: Lippincott-Rave Publishers, 1996: 9-26.
3. Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr 2002; 14 (Suppl. 1): 27-49.
4. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165-70.
5. Wilcock GK, Scott M, Pearsall T, Neubauer K, Boyle M, Razay G. Galantamine and the treatment of Alzheimer's disease. Int J Geriatric Psychiatry 1993; 8: 781-2.
6. Tariot PN, Morris JC, Kershaw P et al. A 5-month placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76.
7. Raskind MA, Peskind ER, Wessel T et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8.
8. Wilcock GK, Lilienfeld S, Gaens E et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomized controlled trial. BMJ 2000; 321: 1445-9.
9. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. Eur J Neurol 2004; 11: 734-41.
10. Thavichachart N, Phanthumchinda K, Chankrachang S et al. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen. Int J Clin Pract 2006; 60: 533-40.
11. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
12. Folstein M, Folstein S, McHugh P. Mini-mental state. A practical method for grading the cognitive status of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
13. Chiu HFK, Lee HC, Chung WS, Kwong PK. Reliability and validity of the cantonese version of Mini-Mental State Examination - a preliminary study. J Hong Kong Coll Psychiatr 1994; 4: 25-8.
14. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64.
15. Chu LW, Chiu KC, Hui SL, Yu GKK, Tsui WJC, Lee PWH. The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-cog) among the elderly Chinese in Hong Kong. Ann Acad Singapore 2000; 29: 478-85.
16. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
17. Galasko D, Bennett D, Sano M et al. An inventory to assess the activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (Suppl. 2): S33-9.
18. Suh GH, Yeon Jung H, Uk Lee C et al. Korean Galantamine Study Group. A prospective, double-blind, community-controlled comparison of three doses of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population. Clin Ther 2004; 26: 1608-18.
19. McKeith IG, Cummings JL, Lovestone S, Harvey RJ, Wilkinson DG, eds. Outcome measures in Alzheimer's disease. London, UK Martin Dunitz 1999; 1-14.
20. Stern RG, Mohs RC, Davidson M et al. A longitudinal study of Alzheimer's disease: measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994; 151: 390-6.
21. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004; 18: 123-8.
22. Murali Doraiswamy P, Kaiser L, Bieber F, Garman RL. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001; 15: 174-83.
23. Chiu KC, Chu LW, Chung CP et al. Clinical features of Alzheimer's disease in a regional Memory Clinic in Hong Kong. J Hong Kong Geriatr Soc 2002; 11: 21-7.
24. Mok WYW, Chu LW, Chung CP, Chan NY, Hui SL. The relationship between non-cognitive symptoms and functional impairment in Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 1040-6.
25. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922-35.